These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35134075)

  • 1. The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma.
    Javier R; Wang W; Drumm M; McCortney K; Sarkaria JN; Horbinski C
    PLoS One; 2022; 17(2):e0257725. PubMed ID: 35134075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo efficacy of decitabine as a natural killer cell-mediated immunotherapy against isocitrate dehydrogenase mutant gliomas.
    Zhang X; Kim WJ; Rao AV; Jaman E; Deibert CP; Sandlesh P; Krueger K; Allen JC; Amankulor NM
    Neurosurg Focus; 2022 Feb; 52(2):E3. PubMed ID: 35104792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.
    Aliotta E; Batchala PP; Schiff D; Lopes BM; Druzgal JT; Mukherjee S; Patel SH
    J Neurooncol; 2019 Nov; 145(2):257-263. PubMed ID: 31531788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors.
    Drumm MR; Wang W; Sears TK; Bell-Burdett K; Javier R; Cotton KY; Webb B; Byrne K; Unruh D; Thirunavu V; Walshon J; Steffens A; McCortney K; Lukas RV; Phillips JJ; Mohamed E; Finan JD; Santana-Santos L; Heimberger AB; Franz CK; Kurz J; Templer JW; Swanson GT; Horbinski C
    J Clin Invest; 2023 Jun; 133(12):. PubMed ID: 37104042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.
    Leu S; von Felten S; Frank S; Boulay JL; Mariani L
    J Neurooncol; 2016 Apr; 127(2):363-72. PubMed ID: 26780338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo Metabolic Profiles as Determined by
    Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
    Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm.
    Guo Y; Ma Z; Pei D; Duan W; Guo Y; Liu Z; Guan F; Wang Z; Xing A; Guo Z; Luo L; Wang W; Yu B; Zhou J; Ji Y; Yan D; Cheng J; Liu X; Yan J; Zhang Z
    J Magn Reson Imaging; 2023 Oct; 58(4):1234-1242. PubMed ID: 36727433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.
    Malta TM; Sabedot TS; Morosini NS; Datta I; Garofano L; Vallentgoed W; Varn FS; Aldape K; D'Angelo F; Bakas S; Barnholtz-Sloan JS; Gan HK; Hasanain M; Hau AC; Johnson KC; Cazacu S; deCarvalho AC; Khasraw M; Kocakavuk E; Kouwenhoven MCM; Migliozzi S; Niclou SP; Niers JM; Ormond DR; Paek SH; Reifenberger G; Sillevis Smitt PA; Smits M; Stead LF; van den Bent MJ; Van Meir EG; Walenkamp A; Weiss T; Weller M; Westerman BA; Ylstra B; Wesseling P; Lasorella A; French PJ; Poisson LM; ; Verhaak RGW; Iavarone A; Noushmehr H
    Cancer Res; 2024 Mar; 84(5):741-756. PubMed ID: 38117484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma.
    Braun Y; Filipski K; Bernatz S; Baumgarten P; Roller B; Zinke J; Zeiner PS; Ilina E; Senft C; Ronellenfitsch MW; Plate KH; Bähr O; Hattingen E; Steinbach JP; Mittelbronn M; Harter PN
    Neuropathol Appl Neurobiol; 2021 Apr; 47(3):379-393. PubMed ID: 33080075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase wt and IDHmut adult-type diffuse gliomas display distinct alterations in ribosome biogenesis and 2'O-methylation of ribosomal RNA.
    Paraqindes H; Mourksi NE; Ballesta S; Hedjam J; Bourdelais F; Fenouil T; Picart T; Catez F; Combe T; Ferrari A; Kielbassa J; Thomas E; Tonon L; Viari A; Attignon V; Carrere M; Perrossier J; Giraud S; Vanbelle C; Gabut M; Bergeron D; Scott MS; Castro Vega L; Magne N; Huillard E; Sanson M; Meyronet D; Diaz JJ; Ducray F; Marcel V; Durand S
    Neuro Oncol; 2023 Dec; 25(12):2191-2206. PubMed ID: 37531290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy.
    Maurer GD; Brucker DP; Bähr O; Harter PN; Hattingen E; Walenta S; Mueller-Klieser W; Steinbach JP; Rieger J
    BMC Cancer; 2011 Jul; 11():315. PubMed ID: 21791085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.
    Aoki K; Suzuki H; Yamamoto T; Yamamoto KN; Maeda S; Okuno Y; Ranjit M; Motomura K; Ohka F; Tanahashi K; Hirano M; Nishikawa T; Shimizu H; Kitano Y; Yamaguchi J; Yamazaki S; Nakamura H; Takahashi M; Narita Y; Nakada M; Deguchi S; Mizoguchi M; Momii Y; Muragaki Y; Abe T; Akimoto J; Wakabayashi T; Saito R; Ogawa S; Haeno H; Natsume A
    Cancer Res; 2021 Sep; 81(18):4861-4873. PubMed ID: 34333454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging.
    Cluceru J; Interian Y; Phillips JJ; Molinaro AM; Luks TL; Alcaide-Leon P; Olson MP; Nair D; LaFontaine M; Shai A; Chunduru P; Pedoia V; Villanueva-Meyer JE; Chang SM; Lupo JM
    Neuro Oncol; 2022 Apr; 24(4):639-652. PubMed ID: 34653254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas.
    Al-Ali R; Bauer K; Park JW; Al Abdulla R; Fermi V; von Deimling A; Herold-Mende C; Mallm JP; Herrmann C; Wick W; Turcan Ş
    Acta Neuropathol Commun; 2019 Dec; 7(1):201. PubMed ID: 31806013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.
    Viswanath P; Radoul M; Izquierdo-Garcia JL; Ong WQ; Luchman HA; Cairncross JG; Huang B; Pieper RO; Phillips JJ; Ronen SM
    Cancer Res; 2018 May; 78(9):2290-2304. PubMed ID: 29358170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.